cenicriviroc Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Cenicriviroc is an experimental drug candidate for the treatment of HIV infection and in combination with Tropifexor for non-alcoholic steatohepatitis. It is being developed by Takeda and Tobira Therapeutics.   Wikipedia

Chemistry

  • SMILES: CCCCOCCOc1ccc(cc1)c2ccc3N(CC(C)C)CCC\C(=C/c3c2)\C(=O)Nc4ccc(cc4)[S@@+]([O-])Cc5cncn5CCC
  • InChIKey: PNDKCRDVVKJPKG-WHERJAGFSA-N
  • Mol. Mass: 696.96
  • ALogP: 8.74
  • ChEMBL Molecules:
    cenicriviroc  
    cenicriviroc mesylate  
More Chemistry

Pharmacology

Alternative names

cenicriviroc | cenicriviroc mesylate | tak 652 | tak-652 | tbr652 | tbr 652 | tbr-652

Organizations (30)

Research & Development (30)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (12)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (12)


 

AIDS Dementia Complex (Phase 2)

Cholangitis, Sclerosing (Phase 2)

COVID-19 (Phase 3)

Diabetes Mellitus, Type 2 (Phase 2)

Healthy Volunteers (Phase 1)

Hepatic Insufficiency (Phase 1)

HIV (Phase 2)

HIV Infections (Phase 2)

Liver Cirrhosis (Phase 2)

Liver Diseases (Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 3)

Prediabetic State (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 19
  • # of Trial Organizations: 30

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue